To further investigate the specific mechanisms affecting the NF-κB signaling pathway and identify therapeutic targets for the treatment of allergic asthma, the study shows that SIRT1 can inhibit the NF-κB signaling pathway and reduce the secretion of inflammatory factors, thereby controlling the inflammatory response of AAI (42–45). Here, NFKB1 is linked to allergic asthma.